Why I think these shares could return more than the ASX 200 by 2030

The S&P/ASX 200 Index (ASX: XJO) has historically delivered returns of around 9% per annum, including dividends.

That's a solid return, but I believe some individual ASX shares could do considerably better than that between now and 2030.

Three shares stand out to me because of their growth opportunities and potential to increase earnings faster than the broader market.

Here's why I'd buy them.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is one of my favourite ASX healthcare shares, and I believe it has enormous opportunities ahead.

The company develops radiopharmaceutical products used to diagnose and potentially treat cancer. Its commercial success so far has largely come from prostate cancer imaging products, including Illuccix and Gozellix.

And I think there's plenty more growth to come from this business. In the September quarter, revenue from its Precision Medicine division increased 30% to US$201 million, supported by demand for both products.

However, what I think investors should be focusing on more is what Telix could achieve as it expands into other areas of cancer care.

Its recently approved Pixclara product gives the company a presence in brain cancer imaging, while its pipeline of potential cancer treatments offers another substantial opportunity.

If Telix can successfully bring more products to market, I believe its revenue and earnings could be considerably larger by 2030.

Clinical trials and regulatory approvals introduce uncertainty, but I think the potential rewards justify considering the shares.

HUB24 Ltd (ASX: HUB)

Another ASX share I think could comfortably outperform the ASX 200 is HUB24.

Its investment platform helps financial advisers manage their clients' investments and superannuation.

I like this business because it has opportunities to benefit from Australia's growing superannuation pool, which is in the trillions of dollars, according to APRA.

And there's good evidence that advisers are increasingly choosing its technology. HUB24 finished September with $168.6 billion in funds under administration, up 15% over the previous year.

It also signed 45 new licensee agreements during the quarter, which could help attract additional client funds onto its platform.

As the amount of money managed through HUB24 increases, so does its opportunity to generate additional revenue. And I believe the company can continue improving profitability as its platform grows.

Of course, the shares already command a premium valuation, and weaker financial markets could affect earnings. Nevertheless, I believe HUB24 has an excellent opportunity to become a substantially larger business by 2030.

Lovisa Holdings Ltd (ASX: LOV)

My final pick is Lovisa, the global jewellery retailer. What I like most about this ASX share is how much room it still has to expand internationally.

According to its annual report, Lovisa finished FY26 with 1,136 stores across more than 50 markets, having opened 160 new locations during the year.

That's a large number, but I believe there are opportunities to open hundreds more over the coming years. Its relatively small store formats and affordable products make the business well suited to expanding across different markets.

We can already see the benefits of this strategy. In FY26, revenue increased 17.6% to $938.8 million, supported by strong growth in Europe and the Americas.

I think Lovisa could deliver impressive earnings growth if it continues opening profitable stores while improving sales at existing locations.

Consumer spending weakness and the challenges of managing a growing international business are risks worth watching. But with several years of expansion potentially ahead, I believe Lovisa has a good chance of outperforming the ASX 200.

Foolish takeaway

Beating the market over a relatively short period isn't guaranteed, even when an ASX share has excellent growth prospects.

However, I believe Telix, HUB24, and Lovisa all have opportunities to become larger businesses between now and 2030.

And if they can translate those opportunities into strong earnings growth, I think shareholders could enjoy returns well above the market's historical average.

The post Why I think these shares could return more than the ASX 200 by 2030 appeared first on The Motley Fool Australia.

Motley Fool contributor Grace Alvino has positions in Hub24 and Lovisa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa and Telix Pharmaceuticals. The Motley Fool Australia has recommended Hub24, Lovisa, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026